StonvexLoading…
StonvexStonvexStonvexImPact Biotech presented updated Phase 1 data showing 71% surgical resection success in LA-PDAC patients and Phase 3 ENLIGHTED trial results demonstrating 70% complete response rates in LG-UTUC with 85.7% durability at 12 months. The company plans to file an NDA for LG-UTUC in 2027 and is investigating accelerated pathways for LA-PDAC.
ImPact Biotech announced updated clinical trial data for Padeliporfin VTP, a vascular-targeted photodynamic therapy. In the Phase 1 LA-PDAC trial, 71% of patients (5/7) achieved successful surgical resection with a well-tolerated safety profile. The Phase 3 ENLIGHTED trial in LG-UTUC showed 70% complete response rates with 85.7% of patients sustaining responses for at least 12 months. The company plans to submit an NDA for LG-UTUC in 2027 and is exploring potential accelerated registrational pathways for LA-PDAC.
Summary and sentiment are generated by AI for educational purposes. Always verify with the original source before making investment decisions.
Risk warning
Investing in equities carries significant risk, including the potential loss of your entire investment. Volatility, liquidity, geopolitical, and currency risks can all materially affect outcomes. Past performance does not guarantee future results. Nothing on Stonvex is investment advice, a recommendation, or a solicitation to buy or sell any security. Stonvex is not a registered investment advisor (RIA), broker-dealer, or financial planner. You should consult a licensed advisor before making investment decisions and only invest capital you can afford to lose.
© 2026 Stonvex. All rights reserved.
Service not available to residents of: Belarus, China, Cuba, France, Germany, India, Iran, Japan, North Korea, Russia, South Korea, Sudan, Syria. See Terms. You must be 18 years or older to use this service.